Logo image of 1VRTX.MI

VERTEX PHARMACEUTICALS INC (1VRTX.MI) Stock Fundamental Analysis

Europe - BIT:1VRTX - US92532F1003 - Common Stock

334.7 EUR
-2.05 (-0.61%)
Last: 9/10/2025, 7:00:00 PM
Fundamental Rating

7

We assign a fundamental rating of 7 out of 10 to 1VRTX. 1VRTX was compared to 75 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making 1VRTX a very profitable company, without any liquidiy or solvency issues. 1VRTX is growing strongly while it is still valued neutral. This is a good combination! With these ratings, 1VRTX could be worth investigating further for growth and quality investing!.


Dividend Valuation Growth Profitability Health

Quickly go to:

7

1. Profitability

1.1 Basic Checks

1VRTX had positive earnings in the past year.
1VRTX had a positive operating cash flow in the past year.
1VRTX had positive earnings in 4 of the past 5 years.
1VRTX had a positive operating cash flow in 4 of the past 5 years.
1VRTX.MI Yearly Net Income VS EBIT VS OCF VS FCF1VRTX.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B 4B

1.2 Ratios

With an excellent Return On Assets value of 15.13%, 1VRTX belongs to the best of the industry, outperforming 86.67% of the companies in the same industry.
1VRTX's Return On Equity of 21.18% is amongst the best of the industry. 1VRTX outperforms 88.00% of its industry peers.
With an excellent Return On Invested Capital value of 16.69%, 1VRTX belongs to the best of the industry, outperforming 90.67% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for 1VRTX is above the industry average of 13.78%.
Industry RankSector Rank
ROA 15.13%
ROE 21.18%
ROIC 16.69%
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)18.67%
ROIC(5y)19.24%
1VRTX.MI Yearly ROA, ROE, ROIC1VRTX.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40

1.3 Margins

The Profit Margin of 1VRTX (31.86%) is better than 86.67% of its industry peers.
The Operating Margin of 1VRTX (38.77%) is better than 92.00% of its industry peers.
1VRTX's Operating Margin has improved in the last couple of years.
1VRTX's Gross Margin of 86.11% is fine compared to the rest of the industry. 1VRTX outperforms 74.67% of its industry peers.
In the last couple of years the Gross Margin of 1VRTX has remained more or less at the same level.
Industry RankSector Rank
OM 38.77%
PM (TTM) 31.86%
GM 86.11%
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
1VRTX.MI Yearly Profit, Operating, Gross Margins1VRTX.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

7

2. Health

2.1 Basic Checks

1VRTX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, 1VRTX has less shares outstanding
The number of shares outstanding for 1VRTX has been reduced compared to 5 years ago.
The debt/assets ratio for 1VRTX has been reduced compared to a year ago.
1VRTX.MI Yearly Shares Outstanding1VRTX.MI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
1VRTX.MI Yearly Total Debt VS Total Assets1VRTX.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

2.2 Solvency

There is no outstanding debt for 1VRTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z N/A
ROIC/WACC1.73
WACC9.64%
1VRTX.MI Yearly LT Debt VS Equity VS FCF1VRTX.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B

2.3 Liquidity

1VRTX has a Current Ratio of 2.52. This indicates that 1VRTX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.52, 1VRTX is in line with its industry, outperforming 56.00% of the companies in the same industry.
1VRTX has a Quick Ratio of 2.16. This indicates that 1VRTX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of 1VRTX (2.16) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.52
Quick Ratio 2.16
1VRTX.MI Yearly Current Assets VS Current Liabilites1VRTX.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B

More info and screens

8

3. Growth

3.1 Past

1VRTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 7966.67%, which is quite impressive.
Measured over the past years, 1VRTX shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -44.14% on average per year.
The Revenue has grown by 10.46% in the past year. This is quite good.
Measured over the past years, 1VRTX shows a very strong growth in Revenue. The Revenue has been growing by 21.50% on average per year.
EPS 1Y (TTM)7966.67%
EPS 3Y-71.86%
EPS 5Y-44.14%
EPS Q2Q%135.23%
Revenue 1Y (TTM)10.46%
Revenue growth 3Y13.31%
Revenue growth 5Y21.5%
Sales Q2Q%12.06%

3.2 Future

The Earnings Per Share is expected to grow by 151.19% on average over the next years. This is a very strong growth
1VRTX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.04% yearly.
EPS Next Y6256.61%
EPS Next 2Y749.77%
EPS Next 3Y329.69%
EPS Next 5Y151.19%
Revenue Next Year10.07%
Revenue Next 2Y9.8%
Revenue Next 3Y9.48%
Revenue Next 5Y10.04%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
1VRTX.MI Yearly Revenue VS Estimates1VRTX.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5B 10B 15B 20B
1VRTX.MI Yearly EPS VS Estimates1VRTX.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 10 20 30

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 23.36, 1VRTX is valued on the expensive side.
Compared to the rest of the industry, the Price/Earnings ratio of 1VRTX indicates a somewhat cheap valuation: 1VRTX is cheaper than 80.00% of the companies listed in the same industry.
1VRTX is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.38, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 18.89, which indicates a rather expensive current valuation of 1VRTX.
81.33% of the companies in the same industry are more expensive than 1VRTX, based on the Price/Forward Earnings ratio.
1VRTX is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 22.86, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 23.36
Fwd PE 18.89
1VRTX.MI Price Earnings VS Forward Price Earnings1VRTX.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, 1VRTX is valued a bit cheaper than the industry average as 76.00% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, 1VRTX is valued a bit cheaper than the industry average as 78.67% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 28.98
EV/EBITDA 20.54
1VRTX.MI Per share data1VRTX.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40 50

4.3 Compensation for Growth

1VRTX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
1VRTX has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as 1VRTX's earnings are expected to grow with 329.69% in the coming years.
PEG (NY)0
PEG (5Y)N/A
EPS Next 2Y749.77%
EPS Next 3Y329.69%

More info and screens

0

5. Dividend

5.1 Amount

1VRTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VERTEX PHARMACEUTICALS INC

BIT:1VRTX (9/10/2025, 7:00:00 PM)

334.7

-2.05 (-0.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-04 2025-08-04/amc
Earnings (Next)11-03 2025-11-03/amc
Inst Owners97.63%
Inst Owner ChangeN/A
Ins Owners0.13%
Ins Owner ChangeN/A
Market Cap85.81B
Analysts75
Price Target425.83 (27.23%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.87%
Min EPS beat(2)-7.2%
Max EPS beat(2)3.45%
EPS beat(4)2
Avg EPS beat(4)-0.78%
Min EPS beat(4)-7.2%
Max EPS beat(4)3.69%
EPS beat(8)5
Avg EPS beat(8)-64.35%
EPS beat(12)7
Avg EPS beat(12)-42%
EPS beat(16)10
Avg EPS beat(16)-30.64%
Revenue beat(2)1
Avg Revenue beat(2)-2.37%
Min Revenue beat(2)-4.8%
Max Revenue beat(2)0.06%
Revenue beat(4)2
Avg Revenue beat(4)-0.57%
Min Revenue beat(4)-4.8%
Max Revenue beat(4)2.68%
Revenue beat(8)3
Avg Revenue beat(8)-0.87%
Revenue beat(12)5
Avg Revenue beat(12)-0.45%
Revenue beat(16)8
Avg Revenue beat(16)0.05%
PT rev (1m)-2.99%
PT rev (3m)-9.41%
EPS NQ rev (1m)0.02%
EPS NQ rev (3m)1.8%
EPS NY rev (1m)0.71%
EPS NY rev (3m)-0.04%
Revenue NQ rev (1m)0.35%
Revenue NQ rev (3m)1.4%
Revenue NY rev (1m)0.46%
Revenue NY rev (3m)0.25%
Valuation
Industry RankSector Rank
PE 23.36
Fwd PE 18.89
P/S 8.88
P/FCF 28.98
P/OCF 26.37
P/B 5.9
P/tB 6.48
EV/EBITDA 20.54
EPS(TTM)14.33
EY4.28%
EPS(NY)17.72
Fwd EY5.29%
FCF(TTM)11.55
FCFY3.45%
OCF(TTM)12.69
OCFY3.79%
SpS37.69
BVpS56.68
TBVpS51.66
PEG (NY)0
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 15.13%
ROE 21.18%
ROCE 22.25%
ROIC 16.69%
ROICexc 24.57%
ROICexgc 27.69%
OM 38.77%
PM (TTM) 31.86%
GM 86.11%
FCFM 30.65%
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)18.67%
ROIC(5y)19.24%
ROICexc(3y)46.18%
ROICexc(5y)52.12%
ROICexgc(3y)66.07%
ROICexgc(5y)80.93%
ROCE(3y)24.89%
ROCE(5y)25.65%
ROICexcg growth 3Y-29.98%
ROICexcg growth 5Y-9.76%
ROICexc growth 3Y-22.64%
ROICexc growth 5Y-1.94%
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
F-Score6
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 173.52%
Cap/Sales 3.04%
Interest Coverage 260.41
Cash Conversion 83.13%
Profit Quality 96.21%
Current Ratio 2.52
Quick Ratio 2.16
Altman-Z N/A
F-Score6
WACC9.64%
ROIC/WACC1.73
Cap/Depr(3y)171.61%
Cap/Depr(5y)187.83%
Cap/Sales(3y)3.11%
Cap/Sales(5y)3.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7966.67%
EPS 3Y-71.86%
EPS 5Y-44.14%
EPS Q2Q%135.23%
EPS Next Y6256.61%
EPS Next 2Y749.77%
EPS Next 3Y329.69%
EPS Next 5Y151.19%
Revenue 1Y (TTM)10.46%
Revenue growth 3Y13.31%
Revenue growth 5Y21.5%
Sales Q2Q%12.06%
Revenue Next Year10.07%
Revenue Next 2Y9.8%
Revenue Next 3Y9.48%
Revenue Next 5Y10.04%
EBIT growth 1Y4.24%
EBIT growth 3Y16.47%
EBIT growth 5Y29.7%
EBIT Next Year816.11%
EBIT Next 3Y130.8%
EBIT Next 5Y68.38%
FCF growth 1Y-9.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-5.45%
OCF growth 3YN/A
OCF growth 5YN/A